Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The mitochondria-dependent apoptotic machinery, commonly referred to as the intrinsic apoptotic pathway, is a fundamental cellular process that executes programmed cell death in response to internal stress signals such as DNA damage, hypoxia, or metabolic imbalance (Source: NIH, StatPearls). This machinery is primarily regulated by the B-cell lymphoma 2 (Bcl-2) family of proteins, which act as a molecular switch to control the integrity of the mitochondrial outer membrane (Source: Nature Reviews Molecular Cell Biology). When pro-apoptotic signals outweigh anti-apoptotic ones, proteins such as Bax and Bak undergo conformational changes and oligomerize to cause mitochondrial outer membrane permeabilization (MOMP), leading to the release of cytochrome c and other pro-apoptotic factors into the cytoplasm (Source: PubMed). These factors facilitate the assembly of the apoptosome and the activation of the caspase cascade, specifically initiator caspase-9 and effector caspases-3 and -7, which ultimately dismantle the cell (Source: UniProt). In many diseases, particularly cancer, this machinery is frequently dysregulated, often through the overexpression of anti-apoptotic proteins like Bcl-2 or Mcl-1, allowing cells to survive despite severe damage (Source: Journal of Clinical Investigation). Therapeutic strategies targeting this machinery, such as BH3 mimetics like venetoclax, aim to restore the apoptotic threshold by inhibiting these survival proteins, thereby inducing selective death in malignant cells (Source: FDA, PubChem).
Induction of apoptosis by inhibiting anti-apoptotic Bcl-2 family proteins (e.g., Bcl-2, Bcl-xL, Mcl-1) or mimicking pro-apoptotic factors (e.g., SMAC) to promote mitochondrial outer membrane permeabilization and subsequent caspase activation.
7 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Mitochondria-dependent apoptotic machinery.